Daniel M Wojdyla Selected Research

apixaban

1/2022	Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS Trial.
1/2022	Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention.
1/2022	Impact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial.
1/2021	Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
1/2021	Premature permanent discontinuation of apixaban or warfarin in patients with atrial fibrillation.
1/2020	Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial.
1/2020	Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial.
1/2020	Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease.
1/2020	Regional variation in clinical characteristics and outcomes in patients with atrial fibrillation: Findings from the ARISTOTLE trial.
12/2019	Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin: Insights From the AUGUSTUS Trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daniel M Wojdyla Research Topics

Disease

37	Atrial Fibrillation 01/2022 - 06/2012
35	Stroke (Strokes) 01/2022 - 08/2011
32	Hemorrhage 01/2022 - 12/2011
18	Acute Coronary Syndrome 01/2022 - 12/2011
13	Myocardial Infarction 01/2022 - 08/2011
13	Embolism (Embolus) 01/2020 - 06/2012
7	Heart Failure 01/2022 - 05/2013
6	Thrombosis (Thrombus) 01/2021 - 07/2013
5	Transient Ischemic Attack 01/2022 - 03/2014
4	Ischemic Stroke 01/2020 - 05/2015
3	Coronary Artery Disease (Coronary Atherosclerosis) 01/2022 - 12/2013
3	Intracranial Hemorrhages (Intracranial Hemorrhage) 01/2017 - 12/2013
2	Thromboembolism 01/2022 - 01/2021
2	Cardiovascular Diseases (Cardiovascular Disease) 07/2020 - 07/2017
2	Chronic Renal Insufficiency 01/2020 - 12/2011
2	Peripheral Arterial Disease 01/2018 - 06/2015
2	Anemia 03/2017 - 03/2014
2	Chronic Obstructive Pulmonary Disease (COPD) 03/2014 - 04/2012
2	Left Ventricular Dysfunction 05/2013 - 01/2012
1	Cardiogenic Shock 01/2022
1	Liver Diseases (Liver Disease) 01/2020
1	Unstable Angina 01/2020
1	Coronary Disease (Coronary Heart Disease) 01/2020
1	Thyroid Diseases (Thyroid Disease) 11/2019
1	Hyperthyroidism 11/2019
1	Hypothyroidism 11/2019
1	Body Weight (Weight, Body) 01/2019
1	Chronic Kidney Failure (Chronic Renal Failure) 01/2018
1	Glucose Intolerance 08/2015
1	Hemorrhagic Stroke 07/2014
1	Hypertension (High Blood Pressure) 12/2013
1	Diabetes Mellitus 09/2013
1	Pathologic Constriction (Stenosis) 07/2013
1	Atrial Flutter (Flutter, Atrial) 06/2012
1	Hyponatremia 01/2012

Drug/Important Bio-Agent (IBA)

35	apixabanIBA 01/2022 - 06/2012
28	Warfarin (Coumadin)FDA LinkGeneric 01/2022 - 06/2012
17	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2022 - 08/2011
10	AnticoagulantsIBA 01/2022 - 08/2015
9	TicagrelorIBA 01/2019 - 08/2011
9	Clopidogrel (Plavix)FDA Link 01/2018 - 08/2011
8	Vitamin K FDA Link 01/2022 - 03/2014
6	Pharmaceutical PreparationsIBA 01/2021 - 12/2011
5	CreatinineIBA 01/2020 - 12/2011
2	alirocumabIBA 01/2022 - 01/2020
2	omega-Chloroacetophenone (Mace)IBA 01/2022 - 01/2020
2	Amiodarone (Amiodarona)FDA LinkGeneric 10/2014 - 09/2014
2	Factor Xa (Coagulation Factor Xa)IBA 07/2014 - 03/2014
2	RivaroxabanIBA 07/2014 - 03/2014
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2022
1	Triglycerides (Triacylglycerol)IBA 07/2020
1	antineoplaston A10 (A 10)IBA 01/2020
1	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2020
1	CreatineIBA 01/2020
1	thienopyridineIBA 01/2019
1	A 19IBA 01/2018
1	bivalirudin (Angiomax)FDA Link 01/2018
1	Heparin (Liquaemin)FDA LinkGeneric 01/2018
1	Digoxin (Digitek)FDA LinkGeneric 01/2018
1	boldenone undecylenate (Equipoise)IBA 06/2017
1	Hemoglobins (Hemoglobin)IBA 03/2017
1	Thrombin Receptors (Thrombin Receptor)IBA 01/2016
1	Nateglinide (Starlix)FDA LinkGeneric 08/2015
1	Valsartan (Vals)FDA Link 08/2015
1	Blood Coagulation Factors (Coagulation Factor)IBA 05/2015
1	Factor VIIa (Activated Factor VII)IBA 05/2015
1	Sotalol (Sotalol Hydrochloride)FDA LinkGeneric 09/2014
1	Anti-Arrhythmia AgentsIBA 09/2014
1	Factor Xa InhibitorsIBA 07/2014
1	Cytochrome P-450 CYP2C19IBA 09/2013
1	Glycoproteins (Glycoprotein)IBA 09/2013
1	MetalsIBA 09/2013
1	N(2)-(3-trifluoromethylphenyl)guanineIBA 07/2013
1	Purinergic P2Y Receptor AntagonistsIBA 12/2011

Therapy/Procedure

16	Therapeutics 01/2022 - 12/2011
11	Percutaneous Coronary Intervention 01/2022 - 04/2014
5	Stents 01/2021 - 09/2013
1	Extracorporeal Membrane Oxygenation 01/2022
1	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 07/2017
1	Polypharmacy 06/2016
1	Blood Transfusion (Blood Transfusions) 05/2015
1	Length of Stay 04/2012
1	Patient Readmission 01/2012